Switzerland And Tokyo
ZUG, Switzerland and TOKYO, May 19, 2011 - Landis+Gyr today announced that Toshiba Corporation (TOKYO: 6502) has
entered into a definitive sale agreement with the shareholders of Landis+Gyr,
under which Toshiba, one of the world's leaders in electronics and power
systems, will acquire Landis+Gyr, the global leader in energy management
solutions for utilities, for US$2.3 billion in cash, to build the world's
Smart Grid leader.
LUGANO, Switzerland and TOKYO, April 13, 2011 - Helsinn Group of Switzerland and Taiho Pharmaceutical Co., Ltd., Japanese
licensee of Helsinn's second generation 5-HT3 receptor antagonist
palonosetron, announce today the signing on April 12, of a licensing
agreement granting Taiho the development and commercialization rights for a
new product for potential use in the prevention of chemotherapy-induced
nausea and vomiting (CINV) in Japan.
BERN, Switzerland and TOKYO, February 22, 2011 - NEC Corporation (NEC; TSE: 6701) and Swisscom AG.
LUGANO, Switzerland and TOKYO, Japan, April 22, 2010 - Helsinn Healthcare SA, Switzerland, and Taiho Pharmaceutical Co., Ltd.,
Japanese licensee of Helsinn's second generation 5-HT3 receptor antagonist
palonosetron, announce the launch of Aloxi(R) injection today.
LUGANO, Switzerland and TOKYO, January 20 - Today, Taiho Pharmaceutical Co., Ltd., Japanese licensee of Helsinn's
second generation 5-HT(3) receptor antagonist palonosetron, gained marketing
approval in Japan for this drug indicated for the prevention of
chemotherapy-induced nausea and vomiting (CINV) (including delayed phase) in
patients with cancer.
